## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($258.98)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Humana (HUM): Wells Fargo Downgrades Rating to Equal-Weight | HU**
- Source: GuruFocus | 20260107T151247 | Somewhat-Bearish | Relevance: 100%
- Wells Fargo has downgraded Humana (HUM) from 'Overweight' to 'Equal-Weight' with a new price target of $290.00 USD. This decision follows recent rating adjustments for Humana by other analysts, reflecting evolving market sentiment for the health insurer. Despite the downgrade, the average analyst target price implies a modest upside, and GuruFocus estimates a significant upside based on its fair value calculations.

**2. Humana Medicare Advantage & Part D Review**
- Source: ValuePenguin | 20260105T220832 | Neutral | Relevance: 100%
- Humana offers Medicare Advantage and Part D plans characterized by generally low rates and good customer service, making it a decent option for many individuals. However, its plans have average overall quality ratings and issues with medication price accuracy. The review details Humana's plan availability, pricing by state, quality ratings, and additional offerings like Medicaid, dental, and vision insurance.

**3. Humana (NYSE:HUM) Price Target Raised to $245.00 at Barclays**
- Source: MarketBeat | 20260105T144515 | Somewhat-Bullish | Relevance: 100%
- Barclays has raised its price target for Humana (NYSE:HUM) to $245.00 from $234.00, maintaining an "equal weight" rating, which suggests a potential downside of 8.99% from the stock's previous close. This adjustment comes after Humana beat earnings and revenue estimates in its most recent quarter, reporting $3.24 EPS against an expected $2.95 and $32.65 billion in revenue. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $294.89, the company's financial performance shows strong year-over-year revenue growth.

**4. Is Weakness In Humana Inc. (NYSE:HUM) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?**
- Source: 富途牛牛 | 20260105T130815 | Somewhat-Bullish | Relevance: 100%
- Despite a recent stock decline, Humana Inc. (NYSE:HUM) exhibits strong financial prospects, supported by an impressive 18% Return on Equity (ROE), significantly above the industry average. The company's consistent earnings growth of 7.9% over the past five years, coupled with a low payout ratio suggesting substantial reinvestment, indicates a healthy financial strategy. Analysts anticipate further acceleration in earnings and a rise in future ROE to 22%, suggesting the market might be overlooking its underlying strengths.

**5. Wells Fargo downgrades Humana to Equal Weight on margin concerns**
- Source: TipRanks | 20260107T112859 | Bearish | Relevance: 100%
- Wells Fargo analyst Stephen Baxter downgraded Humana (HUM) to Equal Weight from Overweight, setting a $290 price target. The downgrade reflects concerns about the achievability of Humana's 2026 margin objectives, particularly due to a lack of benefit cuts for managed care organizations. While Wells Fargo is constructive on Medicare Advantage, they anticipate a more challenging environment for hospitals in 2026 as post-COVID tailwinds diminish and legislative risks increase.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | Wells Fargo | $290 | $0 | 0% |
| 2026-01-05 | Barclays | $245 | $234 | +5% |
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | Wells Fargo | down | Equal-Weight |
| 2026-01-05 | Barclays | main | Equal-Weight |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $33.1B |
| Beta | 0.46 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 22.5 |
| Current P/E | 16.1 |
| YoY Growth | -28.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.4% to 3.9% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. AM_20 at 4.9% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.90), confirming momentum. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.92% (CS: 82) | Neutral |
| RSI_14 | 62.0 | Neutral |
| MACD Histogram | 1.90 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.072x | Above |
| vs SMA200 | 1.063x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $275.20
- **Stop Loss:** $258.98 (5.9% risk)
- **Target:** $307.64 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 73
- **Position Value:** $20,089.60
- **Portfolio %:** 20.09%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*